Desensitization for inhaled vancomycin

Treatment of pulmonary infections in Cystic Fibrosis (CF) can be challenging due to organisms unique to CF and antibiotic resistance (1). Methicillin Resistant Staphylococcus aureus (MRSA) infections are prevalent in patients with CF and have been associated with poor clinical outcomes. The increasing prevalence of MRSA infections in CF has led to the advent of newer modalities of receiving antibiotics such as inhaled therapies. (2) Inhaled vancomycin is often used in the CF population to treat refractory MRSA infections and has been shown to improve clinical outcomes (2-3).
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Tags: Letters Source Type: research